DK1318992T3 - Imidazolderivater som Raf-kinaseinhibitorer - Google Patents

Imidazolderivater som Raf-kinaseinhibitorer

Info

Publication number
DK1318992T3
DK1318992T3 DK01967528T DK01967528T DK1318992T3 DK 1318992 T3 DK1318992 T3 DK 1318992T3 DK 01967528 T DK01967528 T DK 01967528T DK 01967528 T DK01967528 T DK 01967528T DK 1318992 T3 DK1318992 T3 DK 1318992T3
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
raf kinase
imidazole derivatives
migraine
pain
Prior art date
Application number
DK01967528T
Other languages
English (en)
Inventor
Andrew Kenneth Takle
David Kenneth Dean
David Matthew Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0023197A external-priority patent/GB0023197D0/en
Priority claimed from GB0023193A external-priority patent/GB0023193D0/en
Priority claimed from GB0023208A external-priority patent/GB0023208D0/en
Priority claimed from GB0023196A external-priority patent/GB0023196D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DK1318992T3 publication Critical patent/DK1318992T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
DK01967528T 2000-09-21 2001-09-19 Imidazolderivater som Raf-kinaseinhibitorer DK1318992T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0023197A GB0023197D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023193A GB0023193D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023208A GB0023208D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023196A GB0023196D0 (en) 2000-09-21 2000-09-21 Compouds

Publications (1)

Publication Number Publication Date
DK1318992T3 true DK1318992T3 (da) 2005-11-21

Family

ID=27447885

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01967528T DK1318992T3 (da) 2000-09-21 2001-09-19 Imidazolderivater som Raf-kinaseinhibitorer

Country Status (21)

Country Link
US (2) US7199137B2 (da)
EP (1) EP1318992B1 (da)
JP (1) JP2004509882A (da)
KR (1) KR20030030027A (da)
CN (1) CN1471523A (da)
AT (1) ATE300529T1 (da)
AU (1) AU2001287901A1 (da)
BR (1) BR0114023A (da)
CA (1) CA2423154A1 (da)
CY (1) CY1105251T1 (da)
CZ (1) CZ2003793A3 (da)
DE (1) DE60112312T2 (da)
DK (1) DK1318992T3 (da)
ES (1) ES2242767T3 (da)
HU (1) HUP0301181A2 (da)
IL (1) IL154949A0 (da)
MX (1) MXPA03002449A (da)
NO (1) NO20031270L (da)
PL (1) PL361397A1 (da)
PT (1) PT1318992E (da)
WO (1) WO2002024680A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233769B1 (en) 1999-11-22 2007-12-26 SmithKline Beecham plc Imidazole derivatives
EP1263753B1 (en) * 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
US20040053943A1 (en) 2000-11-20 2004-03-18 Adams Jerry L. Novel compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
US20040192689A1 (en) * 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1492568A1 (en) * 2002-04-08 2005-01-05 SmithKline Beecham Corporation Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
JP2006506340A (ja) * 2002-08-09 2006-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
CN101899006B (zh) 2002-08-19 2013-11-06 劳洛斯治疗公司 2，4，5-三取代的咪唑及其作为抗菌剂的用途
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
US20070099250A1 (en) * 2003-04-14 2007-05-03 Ping Hu Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases
JP2007507540A (ja) * 2003-10-02 2007-03-29 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
CA2545942C (en) * 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US8148392B2 (en) 2005-05-25 2012-04-03 Lorus Therapeutics Inc. 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer
CA2622295C (en) * 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
CN101652484B (zh) * 2006-11-08 2013-03-20 密歇根大学董事会 ***癌标志物spink1及其应用
CN101662939B (zh) 2007-02-06 2015-11-25 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
CA2692793C (en) 2007-07-06 2014-05-20 The Regents Of The University Of Michigan Mipol1-etv1 gene rearrangements
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009028629A1 (ja) 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
MX2010003417A (es) * 2007-10-01 2010-09-10 Lixte Biotechnology Inc Inhibidores de histona desacetilasa.
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010064611A1 (ja) 2008-12-01 2010-06-10 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
AU2010295689B2 (en) 2009-09-17 2014-02-13 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20130040983A1 (en) * 2010-01-08 2013-02-14 Jean-Michel Vernier Raf kinase inhibitors
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
AU2014235962A1 (en) 2013-03-20 2015-09-10 Aptose Biosciences Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
DK3052102T3 (da) 2013-10-04 2020-03-09 Aptose Biosciences Inc Sammensætninger til behandling af cancere
WO2019089511A1 (en) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
WO2022249192A1 (en) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
WO1995003297A1 (en) 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
EP0833664A1 (en) 1995-06-12 1998-04-08 G.D. SEARLE & CO. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b 4? receptor antagonist for the treatment of inflammations
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997036587A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. A method of treating cancer
JP3418624B2 (ja) * 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
DE69728986T2 (de) 1996-06-21 2005-04-07 Allergan, Inc., Irvine Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
CA2267186C (en) 1996-10-15 2002-05-14 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
PE10599A1 (es) 1996-10-30 1999-02-10 Schering Corp Derivados de piperazina como antagonistas de neuroquinina
CA2302417A1 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
PL340541A1 (en) 1997-11-14 2001-02-12 Sankyo Co Pyridipyrrole derivative
ATE355856T1 (de) 1998-07-30 2007-03-15 Point Biomedical Corp Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln

Also Published As

Publication number Publication date
US20070135433A1 (en) 2007-06-14
DE60112312T2 (de) 2005-12-29
JP2004509882A (ja) 2004-04-02
CY1105251T1 (el) 2010-03-03
PT1318992E (pt) 2005-11-30
IL154949A0 (en) 2003-10-31
US7199137B2 (en) 2007-04-03
CN1471523A (zh) 2004-01-28
CA2423154A1 (en) 2002-03-28
NO20031270L (no) 2003-05-19
US20040038964A1 (en) 2004-02-26
EP1318992B1 (en) 2005-07-27
WO2002024680A1 (en) 2002-03-28
AU2001287901A1 (en) 2002-04-02
HUP0301181A2 (en) 2007-02-28
BR0114023A (pt) 2004-02-03
EP1318992A1 (en) 2003-06-18
ATE300529T1 (de) 2005-08-15
CZ2003793A3 (cs) 2004-04-14
PL361397A1 (en) 2004-10-04
KR20030030027A (ko) 2003-04-16
MXPA03002449A (es) 2003-06-19
ES2242767T3 (es) 2005-11-16
DE60112312D1 (de) 2005-09-01
NO20031270D0 (no) 2003-03-19

Similar Documents

Publication Publication Date Title
DK1318992T3 (da) Imidazolderivater som Raf-kinaseinhibitorer
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE408601T1 (de) Fredericamycin-derivate
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20052512L (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
SG153851A1 (en) N-(1-(1-benzyl -4-phenyl-1h-imidazol-2-yl)-2,2-dymethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
WO2003080582A3 (de) Fredericamycin-derivate
ATE386034T1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
ATE484508T1 (de) Furylverbindungen
GB0112348D0 (en) Compounds
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
ATE468341T1 (de) Thienopyrazole
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
GB0121494D0 (en) Compounds
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
BRPI0415390A (pt) compostos de pirazinona substituìda para o tratamento da inflamação
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren